Insights+: The US FDA New Drug Approvals in February 2023

Shots:The US FDA approved 5 NDAs and 5 BLA in February 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 19 novel products in 2023In February 2023, the major highlights drugs were, Tezspire (tezepelumab) approval for severe asthma, Altuviiio for hemophilia APharmaShots has compiled…

BySenior EditorMarch 15, 2023

INSIGHTS+

Disease of the Month: Age-Related Macular Degeneration

Introduction:AMD, an eye disease that can cause of loss of eyesight/blur vision mostly in people ≥50 years of age and it is the leading cause of visual impairment worldwide.It occurs when the part of the retina (macula) is damaged. Patients lose their central vision and cannot see fine detailsThe three stages of…

BySenior EditorFebruary 9, 2023

TOP 20

Top 20 Prescription Drugs Based on 2021 Total Revenue

Shots:The pharmaceutical companies have shown continual efforts towards developing enhanced and innovative treatment options to address the unmet needs of patients with disease eradication being the goal of developing these treatmentsAdvancements in cellular and molecular biology have increased the possibilities for generating new pharmaceutical products imposing major impacts on the prevention, diagnosis, and…

ByPrince GiriNovember 10, 2022

INSIGHTS+

Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: AfliberceptStrength: 2 mg (0.05 mL)Dosage Form: Injection (intravitreal)Mechanism of Action: VEGF-A and PlGF inhibitorsFirst Approval: US (18 Nov 2011), EU (27 Nov 2012)Revenue1EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…

BySenior EditorSeptember 22, 2022

INSIGHTS+

Top Performing Drug of 2021 – Humira (April Edition)

Active Ingredients: AdalimumabStrength: 40 mg/0.8 mlDosage Form: Syringe, VialMechanism of Action: TNF-alpha inhibitorsFirst Approval: US (Dec 31, 2002), EU (Aug 09, 2003)RevenueHumira (adalimumab) has been the top-selling biologic drug product for the last few years – reaching nearly $21B in annual sales in 2021. Humira is one of the main drivers of AbbVie’s immunology…

BySenior EditorApril 29, 2022

INSIGHTS+

Top Performing Drugs of 2021: A Monthly Series by PharmaShots

The year 2021 witnessed the global approval of vaccines and drugs amid COVID-19. The disease has been dominating the headlines from the last two years.No one is amazed that COVID vaccines and drugs find a place in top selling drugs this time. Pfizer & BioNTech’s Comirnaty took the first position with $36B revenue and…

BySenior EditorApril 28, 2022

TOP 20

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology- cardiology- and neurology but are they…

ByPrince GiriJuly 17, 2020

Insights+: The US FDA New Drug Approvals in February 2023

Disease of the Month: Age-Related Macular Degeneration

Top 20 Prescription Drugs Based on 2021 Total Revenue

Top Performing Drug of 2021 – Humira (April Edition)

Top Performing Drugs of 2021: A Monthly Series by PharmaShots

Top 20 Prescription Drugs Based on 2019 Revenue

Contact US

OUR INFORMATION

FOLLOW US